_version_ 1784902064893067264
author Uraki, Ryuta
Ito, Mutsumi
Kiso, Maki
Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Sakai-Tagawa, Yuko
Furusawa, Yuri
Imai, Masaki
Koga, Michiko
Yamamoto, Shinya
Adachi, Eisuke
Saito, Makoto
Tsutsumi, Takeya
Otani, Amato
Kashima, Yukie
Kikuchi, Tetsuhiro
Yotsuyanagi, Hiroshi
Suzuki, Yutaka
Kawaoka, Yoshihiro
author_facet Uraki, Ryuta
Ito, Mutsumi
Kiso, Maki
Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Sakai-Tagawa, Yuko
Furusawa, Yuri
Imai, Masaki
Koga, Michiko
Yamamoto, Shinya
Adachi, Eisuke
Saito, Makoto
Tsutsumi, Takeya
Otani, Amato
Kashima, Yukie
Kikuchi, Tetsuhiro
Yotsuyanagi, Hiroshi
Suzuki, Yutaka
Kawaoka, Yoshihiro
author_sort Uraki, Ryuta
collection PubMed
description
format Online
Article
Text
id pubmed-9991060
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-99910602023-03-08 Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1 Uraki, Ryuta Ito, Mutsumi Kiso, Maki Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Sakai-Tagawa, Yuko Furusawa, Yuri Imai, Masaki Koga, Michiko Yamamoto, Shinya Adachi, Eisuke Saito, Makoto Tsutsumi, Takeya Otani, Amato Kashima, Yukie Kikuchi, Tetsuhiro Yotsuyanagi, Hiroshi Suzuki, Yutaka Kawaoka, Yoshihiro Lancet Infect Dis Correspondence Elsevier Ltd. 2023-05 2023-03-07 /pmc/articles/PMC9991060/ /pubmed/36898405 http://dx.doi.org/10.1016/S1473-3099(23)00132-9 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Uraki, Ryuta
Ito, Mutsumi
Kiso, Maki
Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Sakai-Tagawa, Yuko
Furusawa, Yuri
Imai, Masaki
Koga, Michiko
Yamamoto, Shinya
Adachi, Eisuke
Saito, Makoto
Tsutsumi, Takeya
Otani, Amato
Kashima, Yukie
Kikuchi, Tetsuhiro
Yotsuyanagi, Hiroshi
Suzuki, Yutaka
Kawaoka, Yoshihiro
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
title Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
title_full Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
title_fullStr Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
title_full_unstemmed Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
title_short Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
title_sort efficacy of antivirals and bivalent mrna vaccines against sars-cov-2 isolate ch.1.1
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991060/
https://www.ncbi.nlm.nih.gov/pubmed/36898405
http://dx.doi.org/10.1016/S1473-3099(23)00132-9
work_keys_str_mv AT urakiryuta efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT itomutsumi efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT kisomaki efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT yamayoshiseiya efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT iwatsukihorimotokiyoko efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT sakaitagawayuko efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT furusawayuri efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT imaimasaki efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT kogamichiko efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT yamamotoshinya efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT adachieisuke efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT saitomakoto efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT tsutsumitakeya efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT otaniamato efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT kashimayukie efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT kikuchitetsuhiro efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT yotsuyanagihiroshi efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT suzukiyutaka efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11
AT kawaokayoshihiro efficacyofantiviralsandbivalentmrnavaccinesagainstsarscov2isolatech11